Autoimmune liver diseases and antiphospholipid antibodies positivity: A meta-analysis of literature studies

Journal of Gastrointestinal and Liver Diseases

Volumn 24, Issue 1, 2015, Pages 25-34

  Ambrosino, Pasquale ^a   Lupoli, Roberta ^a   Spadarella, Gaia ^a   Tarantino, Paolo ^a   Di Minno, Alessandro ^a   Tarantino, Luciano ^b   Di Minno, Matteo Nicola Dario ^a,c  

^a UNIVERSITY OF NAPLES FEDERICO II   (Italy)

^b Andrea Tortora Hospital   (Italy)

^c CENTRO CARDIOLOGICO MONZINO   (Italy)

Author keywords

Antiphospholipid antibodies; Antiphospholipid syndrome; Autoimmune hepatitis; Primary biliary cirrhosis; Primary sclerosing cholangitis

Indexed keywords

ANTIBODY; BETA 2 GLYCOPROTEIN ANTIBODY; CARDIOLIPIN ANTIBODY; IMMUNOGLOBULIN A; IMMUNOGLOBULIN G; IMMUNOGLOBULIN M; LUPUS ANTICOAGULANT ANTIBODY; PHOSPHOLIPID ANTIBODY; UNCLASSIFIED DRUG;

ARTICLE; AUTOIMMUNE HEPATITIS; BILIARY CIRRHOSIS; DATA EXTRACTION; DISEASE ASSOCIATION; HUMAN; META ANALYSIS; PUBLICATION; SCLEROSING CHOLANGITIS; SENSITIVITY ANALYSIS; SYSTEMATIC REVIEW; THROMBOSIS; ANTIPHOSPHOLIPID SYNDROME; AUTOIMMUNITY; BLOOD; CHI SQUARE DISTRIBUTION; CHOLANGITIS, SCLEROSING; HEPATITIS, AUTOIMMUNE; IMMUNOLOGY; LIVER CIRRHOSIS, BILIARY; ODDS RATIO; PROGNOSIS; RISK FACTOR;

ANTIBODIES, ANTIPHOSPHOLIPID; ANTIPHOSPHOLIPID SYNDROME; AUTOIMMUNITY; CHI-SQUARE DISTRIBUTION; CHOLANGITIS, SCLEROSING; HEPATITIS, AUTOIMMUNE; HUMANS; LIVER CIRRHOSIS, BILIARY; ODDS RATIO; PROGNOSIS; RISK FACTORS; THROMBOSIS;

EID: 84924125305     PISSN: 18418724     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (47)

1. Wilson WA, Gharavi AE, Koike T, et al. International consensus statement on preliminary classification criteria for definite antiphospholipid syndrome: report of an international workshop. Arthritis Rheum 1999; 42: 1309-1311. doi: 10. 1002/1529-0131(199907)42: 7<1309:: AID-ANR1>3. 0. CO; 2-F.
2. Miyakis S, Lockshin MD, Atsumi T, et al. International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS). J Thromb Haemost 2006; 4: 295-306. doi: 10. 1111/j. 1538-7836. 2006. 01753. x.
3. Levine JS, Branch DW, Rauch J. The antiphospholipid syndrome. N Engl J Med 2002; 346: 752-763. doi: 10. 1056/NEJMra002974.
4. Mullen MT, Messé SR, Kasner SE, et al. Anti-Phosphatidylserine-Prothrombin Antibodies are Associated with Outcome in a TIA Cohort. Front Neurol 2012; 3: 137. doi: 10. 3389/fneur. 2012. 00137.
5. Gómez-Puerta JA, Cervera R. Diagnosis and classification of the antiphospholipid syndrome. J Autoimmun 2014; 48-49: 20-25. doi: 10. 1016/j. jaut. 2014. 01. 006.
6. Mehrania T, Petri M. Epidemiology of the antiphospholipid syndrome. Amsterdam: Elsevier 2009.
7. Love PE, Santoro SA. Antiphospholipid antibodies: anticardiolipin and the lupus anticoagulant in systemic lupus erythematosus (SLE) and in non-SLE disorders. Prevalence and clinical significance. Ann Intern Med 1990; 112: 682-698. doi: 10. 7326/0003-4819-112-9-682.
8. Petrogiannopoulos C, Papamichael K, Goumas K, Soutos D. Autoimmune liver disease. Ann Gastroenterol 2004; 17: 51-58.
9. Mayo MJ. Cholestatic liver disease overlap syndromes. Clin Liver Dis 2013; 17: 243-253. doi: 10. 1016/j. cld. 2012. 12. 006.
10. Achenza MI, Meda F, Brunetta E, Selmi C. Serum autoantibodies for the diagnosis and management of autoimmune liver diseases. Expert Rev Gastroenterol Hepatol 2012; 6: 717-729. doi: 10. 1586/egh. 12. 58.
11. Mackay IR, Whittingham S, Fida S, et al. The peculiar autoimmunity of primary biliary cirrhosis. Immunol Rev 2000; 174: 226-237. doi: 10. 1034/j. 1600-0528. 2002. 017410. x.
12. Rigopoulou EI, Davies ET, Pares A, et al. Prevalence and clinical significance of isotype specific antinuclear antibodies in primary biliary cirrhosis. Gut 2005; 54: 528-532. doi: 10. 1136/gut. 2003. 036558.
13. Czaja AJ. The overlap syndromes of autoimmune hepatitis. Dig Dis Sci 2013; 58: 326-343. doi: 10. 1007/s10620-012-2367-1.
14. Bogdanos DP, Invernizzi P, Mackay IR, Vergani D. Autoimmune liver serology: current diagnostic and clinical challenges. World J Gastroenterol 2008; 14: 3374-3387. doi: 10. 3748/wjg. 14. 3374.
15. Gabeta S, Norman GL, Gatselis N, et al. IgA anti-b2GPI antibodies in patients with autoimmune liver diseases. J Clin Immunol 2008; 28: 501-511. doi: 10. 1007/s10875-008-9211-6.
16. Liaskos C, Rigopoulou E, Zachou K, et al. Prevalence and clinical significance of anticardiolipin antibodies in patients with type 1 autoimmune hepatitis. J Autoimmun 2005; 24: 251-260. doi: 10. 1016/j. jaut. 2005. 01. 016.
17. Zachou K, Liaskos C, Rigopoulou E, et al. Presence of high avidity anticardiolipin antibodies in patients with autoimmune cholestatic liver diseases. Clin Immunol 2006; 119: 203-212. doi: 10. 1016/j. clim. 2006. 01. 002.
18. Saeki R, Kaneko S, Terasaki S, et al. Mixed types of chronic active hepatitis and primary biliary cirrhosis associated with the anti-phospholipid antibody syndrome: a case report. Hepatogastroenterology 1993; 40: 499-501.
19. Cholongitas E, Mavrogiannaki A, Papaioannou C, Karagiannis S, Papatheodoridis GV. Pericarditis and possible antiphospholipid syndrome on primary biliary cirrhosis. Ann Hepatol 2004; 43: 167-168.
20. de Larranaga GF, Harris N, Pierangeli SS, Alonso BS, Schroder T, Fainboim H. Low prevalence of autoimmune antiphospholipid antibodies in hepatic diseases. Medicina 2000; 60: 919-922.
21. Moher D, Liberati A, Tetzlaff J, Altman DG; PRISMA Group. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLOS Med 2009; 6: e1000097. doi: 10. 1371/journal. pmed1000097.
22. Wells GA, Shea B, O'Connell D, et al. Ottawa Hospital Research Institute. The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomized studies in meta-analyses. Available from: URL: www. ohri. ca/programs/clinical_epidemiology/oxford. htm.
23. Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ 2003; 327: 557-560. doi: 10. 1136/bmj. 327. 7414. 557.
24. Sterne JA, Egger M, Smith GD. Systematic reviews in health care: investigating and dealing with publication and other biases in meta-analysis. BMJ 2001; 323: 101-105. doi: 10. 1136/bmj. 323. 7304. 101.
25. Klein R, Goller S, Bianchi L. Nodular regenerative hyperplasia (NRH) of the liver--a manifestation of 'organ-specific antiphospholipid syndrome'? Immunobiology 2003; 207: 51-57. doi: 10. 1078/0171-2985-00209.
26. von Landenberg P, Baumgartner M, Schoelmerich J, Lackner KJ, Klein R. Clinical relevance of antiphospholipid antibodies in primary biliary cirrhosis. Ann N Y Acad Sci 2005; 1051: 20-28. doi: 10. 1196/annals. 1361. 043.
27. Branger S, Schleinitz N, Veit V, et al. Auto-immune hepatitis and antiphospholipids. Rev Med Interne 2007; 28: 218-224. doi: 10. 1016/j. revmed. 2006. 12. 005.
28. Font J, Cervera R, Lopez-Soto A, et al. Anticardiolipin antibodies in patients with autoimmune diseases: isotype distribution and clinical associations. Clin Rheumatol 1989; 8: 475-483.
29. Harada M, Fujisawa Y, Sakisaka S, et al. High prevalence of anticardiolipin antibodies in hepatitis C virus infection: lack of effects on thrombocytopenia and thrombotic complications. J Gastroenterol 2000; 35: 272-277.
30. Mankaï A, Manoubi W, Ghozzi M, Melayah S, Sakly W, Ghedira I. High Frequency of antiphospholipid antibodies in primary biliary cirrhosis. J Clin Lab Anal 2015; 29: 32-36. doi: 10. 1002/jcla. 21723.
31. Angulo P, Grandison GA, Fong DG, et al. Bone disease in patients with primary sclerosing cholangitis. Gastroenterology 2011; 140: 180-188. doi: 10. 1053/j. gastro. 2010. 10. 014.
32. Agmon-Levin N, Shapira Y, Selmi C, et al. A comprehensive evaluation of serum autoantibodies in primary biliary cirrhosis. J Autoimmun 2010; 34: 55-58. doi: 10. 1016/j. jaut. 2009. 08. 009.
33. Hughes GR, Harris EN, Gharavi AE. The anticardiolipin syndrome. J Rheumatol 1986; 13: 486-489.
34. Hoffman M, Burke M, Fried M, Turner D, Yosipov Y, Yust I. Primary biliary cirrhosis associated with antiphospholipid syndrome. Isr J Med Sci 1997; 33: 681-686.
35. Aspinall AI, Lee SS. Concurrence of primary biliary cirrhosis and antiphospholipid antibody syndrome. Am J Gastroenterol 2004; 99: 2069-2070. doi: 10. 1111/j. 1572-0241. 2004. 40680_6. x.
36. Elefsiniotis IS, Diamantis ID, Dourakis SP, Kafiri G, Pantazis K, Mavrogiannis C. Anticardiolipin antibodies in chronic hepatitis B and chronic hepatitis D infection, and hepatitis B-related hepatocellular carcinoma. Relationship with portal vein thrombosis. Eur J Gastroenterol Hepatol 2003; 15: 721-726. doi: 10. 1097/01. meg. 0000059140. 68845. 74.
37. Zachou K, Liaskos C, Christodoulou DK, et al. Anti-cardiolipin antibodies in patients with chronic viral hepatitis are independent of beta2-glycoprotein I cofactor or features of antiphospholipid syndrome. Eur J Clin Invest 2003; 33: 161-168. doi: 10. 1046/j. 1365-2362. 2003. 01110. x.
38. Mangia A, Margaglione M, Cascavilla I, et al. Anticardiolipin antibodies in patients with liver disease. Am J Gastroenterol 1999; 94: 2983-2987. doi: 10. 1111/j. 1572-0241. 1999. 01447. x.
39. Ernster L, Schatz G. Mitochondria: A historical review. J Cell Biol 1981; 91: 227s-255s.
40. Reynaud Q, Lega JC, Mismetti P, et al. Risk of venous and arterial thrombosis according to type of antiphospholipid antibodies in adults without systemic lupus erythematosus: a systematic review and meta-analysis. Autoimmun Rev 2014; 13: 595-608. doi: 10. 1016/j. autrev. 2013. 11. 004.
41. Meijide H, Sciascia S, Sanna G, Khamashta MA, Bertolaccini ML. The clinical relevance of IgA anticardiolipin and IgA anti-β2 glycoprotein I antiphospholipid antibodies: a systematic review. Autoimmun Rev 2013; 12: 421-425. doi: 10. 1016/j. autrev. 2012. 08. 002.
42. Andreoli L, Fredi M, Nalli C, et al. Clinical significance of IgA anti-cardiolipin and IgA anti-β2glycoprotein I antibodies. Curr Rheumatol Rep 2013; 15: 343. doi: 10. 1007/s11926-013-0343-1.
43. Petri M, Orbai AM, Alarcón GS, et al. Derivation and validation of the Systemic Lupus International Collaborating Clinics classification criteria for systemic lupus erythematosus. Arthritis Rheum 2012; 64: 2677-2686. doi: 10. 1002/art. 34473.
44. Abe M, MasumotoT, Ninomiya T, et al. Hyperplastic liver nodules associated with early-stage primary biliary cirrhosis mimicking hepatocellular carcinoma. Dig Dis Sci 2000; 45: 1563-1567.
45. Gores GJ, Wiesner RH, Dickson ER, Zinsmeister AR, Jorgensen RA, Langworthy A. Prospective evaluation of esophageal varices in primary biliary cirrhosis: development, natural history, and influence on survival. Gastroenterology 1989; 96: 1552-1559.
46. Huet PM, Vincent C, Deslaurier J, et al. Portal hypertension and primary biliary cirrhosis: effect of long-term ursodeoxycholic acid treatment. Gastroenterology 2008; 135: 1552-1560. doi: 10. 1053/j. gastro. 2008. 07. 019.
47. Higgins JP, Green S. Cochrane handbook for systematic reviews of interventions. Version 5. 1. 0 [updated March 2011]. The Cochrane Collaboration. Available from: URL: www. cochrane-handbook. org.